Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past CO⦠read more
Healthcare
Biotechnology
4 years
USD
Exclusive to Premium users
$13.04
Price+0.93%
$0.12
$1.986b
Small
-
Premium
Premium
-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin$205.216m
-
1y CAGR-
3y CAGR-
5y CAGR-$121.229m
-
1y CAGR-
3y CAGR-
5y CAGR-$0.82
-
1y CAGR-
3y CAGR-
5y CAGR$179.536m
$496.637m
Assets$317.101m
Liabilities$84.370m
Debt17.0%
-0.9x
Debt to EBITDA-$82.808m
-
1y CAGR-
3y CAGR-
5y CAGR